Progyny, Inc. (PGNY) Stock Price & Analysis
Progyny, Inc. (PGNY) rose 1.60% to USD 31.19 as of July 25, 2026 at 06:43 UTC, according to Nexqual real-time market data.
PGNY last closed at USD 30.7; the session ranged USD 30.83–31.73 on volume of 619,582 shares. Market capitalization is $2.44B, with a 52-week range of USD 16.1–33.07 (NMS). Source: Nexqual, July 25, 2026 at 06:43 UTC.
Key Statistics (as of July 25, 2026 at 06:43 UTC)
| Price | USD 31.19 |
|---|---|
| Change | ▲ 1.60% (up) |
| Previous Close | USD 30.7 |
| Open | USD 31.45 |
| Day Range | USD 30.83 – 31.73 |
| 52-Week Range | USD 16.1 – 33.07 |
| Volume | 619,582 shares |
| Market Cap | $2.44B |
| Exchange | NMS |
Technical Analysis (PGNY)
Nexqual's technical model rates PGNY "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.74 (neutral) |
| vs SMA50 | Above (USD 27.67) |
| MACD | 1.25 (positive) |
Analyst Ratings (PGNY)
Wall Street analysts rate PGNY "Strong Buy" based on 11 analysts, with a mean price target of USD 32.45 (range USD 27–38), per Nexqual as of July 25, 2026 at 06:43 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 32.45 |
| High Target | USD 38 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (PGNY)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.52 |
| Revenue Estimate | $348.65M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.5 vs est 0.44 ▲ beat |
| 2025-12-31 | USD 0.48 vs est 0.4 ▲ beat |
| 2025-09-30 | USD 0.45 vs est 0.39 ▲ beat |
| 2025-06-30 | USD 0.48 vs est 0.43 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:43 UTC.
Financials & Fundamentals (PGNY)
| Total Revenue | $1.29B |
|---|---|
| Revenue Growth (YoY) | +1.40% |
| Gross Margin | +24.11% |
| Operating Margin | +10.77% |
| Profit Margin | +5.24% |
| ROE | +14.94% |
| Debt / Equity | 6.21 |
| Current Ratio | 2.13 |
| Total Cash | $225.11M |
| Total Debt | $27.28M |
| Free Cash Flow | $200.21M |
Source: Nexqual, July 25, 2026 at 06:43 UTC.
Financial Health Score (PGNY)
Nexqual rates Progyny, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 06:43 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 24%, operating 11% |
| Balance Sheet | Strong — $225M cash vs $27M debt, net cash position |
| Cash Flow | Strong — FCF $200M, 16% margin |
| Efficiency | Mixed — ROE 15%, ROA 9.1% |
Ownership (PGNY)
| Insider Ownership | +1.95% |
|---|---|
| Institutional Ownership | +112.28% |
| Shares Outstanding | 78.33M |
| Float | 71.66M |
| Short % of Float | +8.28% |
Source: Nexqual, July 25, 2026 at 06:43 UTC.
Leadership (PGNY)
Progyny, Inc. is led by Peter Anevski (age 58), CEO & Director, per Nexqual as of July 25, 2026 at 06:43 UTC.
| CEO & Director | Peter Anevski (age 58) |
|---|---|
| Executive Chairman | David J. Schlanger (age 66) |
| Chief Financial Officer | Mark S. Livingston (age 59) |
| Chief Operating Officer | Melissa B. Cummings (age 55) |
| Chief Product Officer | Geoffrey Clapp (age 51) |
Major Backers & Investors (PGNY)
Notable institutional backers of Progyny, Inc. include FMR, LLC, Fidelity, Ameriprise Financial, Inc., according to Nexqual as of July 25, 2026 at 06:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.3% |
| Fidelity | 4.17% |
| Ameriprise Financial, Inc. | 3.61% |
| Fort Washington Investment Advisors, Inc. | 3.25% |
| Wellington Management | 2.92% |
| Morgan Stanley | 2.92% |
| Soleus Capital Management, L.P. | 2.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.81% |
| Vanguard Group | 19.03% |
| State Street | 3.93% |
Source: Nexqual, July 25, 2026 at 06:43 UTC.
From Progyny, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our cybersecurity risk management program incorporates industry-standard frameworks, policies and practices designed to protect the security of our technology infrastructure and sensitive information.
Partnerships
- We have experienced and may in the future experience fluctuations in our financial results, making it difficult to project future results, and if we fail to meet the expectations of securities analysts or investors with respect to our results of operations, our stock price and the value of your investment could decline.
- Share Repurchase Program On November 5, 2025, the Company announced the November 2025 share repurchase program (the "November 2025 share repurchase program") of up to $200 million of shares of common stock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INMD | InMode Ltd. | USD 15.17 | ▼ 0.2% |
| SPT | Sprout Social, Inc | USD 7.57 | ▼ 0.53% |
| OM | Outset Medical, Inc. | USD 4.04 | ▼ 2.18% |
| TXG | 10x Genomics, Inc. | USD 46.27 | ▼ 1.66% |
| HCAT | Health Catalyst, Inc | USD 2.08 | ▲ 1.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:43 UTC. This page is informational and not investment advice.